Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The induction of autoimmune diseases during tumour necrosis factor-alpha inhibitor (TNFi) usage has been described. Herein, we report a rare case of a 49-year-old woman with antimelanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM), which developed 5 weeks after the introduction of an etanercept biosimilar to rheumatoid arthritis (RA). Four of the five known cases, including ours, of anti-MDA5Ab-positive DM complicated with RA revealed anti-MDA5Ab-positive DM following TNFi usage. When patients with RA are diagnosed with interstitial lung disease during TNFi usage, anti-MDA5 Ab-positive DM could be a differential diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/mrcr/rxae013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patterns of Use and Discontinuation for Tumor Necrosis Factor Inhibitors in Pregnant Women: Insights From a Real-World Sample.
J Rheumatol
August 2025
É. Vinet, MD, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Department of Medicine, Faculty of Medicine, McGill University, Montre
Objective: We aimed to evaluate tumor necrosis factor inhibitor (TNFi) usage patterns in pregnant women with rheumatoid arthritis (RA), radiographic axial spondyloarthritis (r-axSpA), psoriatic arthritis (PsA), psoriasis (PsO), and inflammatory bowel diseases (IBD), and to compare corticosteroid use in those discontinuing TNFi at specific gestational timepoints vs those continuing throughout gestation.
Methods: We analyzed pregnancies resulting in a live birth among women with RA, r-axSpA, PsA, PsO, and/or IBD, aged 15-45 years, who were hospitalized for delivery between January 2011 and December 2021, using the MarketScan commercial claims database. TNFi exposure was defined as ≥ 1 filled prescription or infusion procedure claim for a TNFi.
Comparative Effectiveness of TNF-α and IL-6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study.
Int J Rheum Dis
June 2025
Department of Internal Medicine, Taitung Hospital, Ministry of Health and Welfare, Taitung, Taiwan.
Background: Rheumatoid arthritis (RA) significantly impacts bone health, leading to osteoporosis and increased fracture risks. This study aims to compare the effects of TNF-α and IL-6 inhibitors on the incidence of fractures, osteoporosis, and mortality among RA patients.
Methods: We conducted a retrospective cohort study using the TriNetX database, spanning from January 1, 2015, to December 31, 2022.
Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis.
Innate Immun
May 2025
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the synovial joint linings, resulting in progressive disability, increased mortality, and considerable economic costs. Early treatment with disease-modifying antirheumatic medications (DMARDs) can significantly improve the overall outlook for people with RA. Contemporary pharmaceutical interventions, encompassing standard, biological, and emerging small molecule disease- modifying anti-rheumatic medications continue to be the cornerstone of RA management, with substantial advancements made in the pursuit of achieving remission from the disease and preventing joint deformities.
View Article and Find Full Text PDFRisk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study.
Sci Rep
March 2025
Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.
This retrospective cohort study included all user of tumor necrosis factor-α inhibitors (TNFi), including etanercept, infliximab, adalimumab, and golimumab, among Korean patients with psoriasis and rheumatoid arthritis (N of user = 7,645) and the non-user who was diagnosed with same diseases, never used TNFi, and was served as the reference. Cumulative usage of TNFi was calculated between the newly diagnosed date and index date (2-year from the diagnosed date). Adjusted hazard ratio (aHR [95% confidence intervals (CIs)]) for colorectal, liver, lung, kidney, breast, and thyroid cancer were not significantly increased or decreased: 0.
View Article and Find Full Text PDFPortuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy - a delphi methodology.
J Dermatolog Treat
December 2025
Dermatology Department, Hospital de S. José, Unidade Local de Saúde São José, Lisboa, Portugal.
Introduction: Psoriasis (PsO) is a common chronic, inflammatory, immune-mediated disease. In 2023, a 4.4% prevalence of PsO was reported in Portugal.
View Article and Find Full Text PDF